- Home
- IPW vs PSTV Comparison
IPW vs PSTV Comparison
Compare IPW & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPW
- PSTV
- Stock Information
- Founded
- IPW 2018
- PSTV 1996
- Country
- IPW United States
- PSTV United States
- Employees
- IPW N/A
- PSTV N/A
- Industry
- IPW Catalog/Specialty Distribution
- PSTV Medical/Dental Instruments
- Sector
- IPW Consumer Discretionary
- PSTV Health Care
- Exchange
- IPW Nasdaq
- PSTV Nasdaq
- Market Cap
- IPW 14.4M
- PSTV 17.0M
- IPO Year
- IPW 2021
- PSTV N/A
- Fundamental
- Price
- IPW $0.66
- PSTV $0.53
- Analyst Decision
- IPW
- PSTV Strong Buy
- Analyst Count
- IPW 0
- PSTV 3
- Target Price
- IPW N/A
- PSTV $10.83
- AVG Volume (30 Days)
- IPW 189.7K
- PSTV 19.1M
- Earning Date
- IPW 09-18-2025
- PSTV 08-13-2025
- Dividend Yield
- IPW N/A
- PSTV N/A
- EPS Growth
- IPW N/A
- PSTV N/A
- EPS
- IPW N/A
- PSTV N/A
- Revenue
- IPW $74,105,251.00
- PSTV $5,206,000.00
- Revenue This Year
- IPW $8.31
- PSTV $14.10
- Revenue Next Year
- IPW $77.15
- PSTV $7.96
- P/E Ratio
- IPW N/A
- PSTV N/A
- Revenue Growth
- IPW N/A
- PSTV N/A
- 52 Week Low
- IPW $0.41
- PSTV $0.16
- 52 Week High
- IPW $2.36
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- IPW 51.56
- PSTV 64.56
- Support Level
- IPW $0.61
- PSTV $0.27
- Resistance Level
- IPW $0.72
- PSTV $0.71
- Average True Range (ATR)
- IPW 0.05
- PSTV 0.05
- MACD
- IPW -0.01
- PSTV 0.03
- Stochastic Oscillator
- IPW 28.31
- PSTV 53.79
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).